Summary
The purpose of this study is to determine the safety and tolerability of revumenib when
given in combination with 2 different chemotherapy regimens in participants with
relapsed/refractory acute leukemias harboring KMT2A rearrangement, KMT2A amplification,
NPM1c, or NUP98r.